Paul A. Mahon, EVP & General Counsel at United Therapeutics (UTHR), has demonstrated a consistent pattern of selling activity in the company’s stock, with no recent purchases recorded in SEC filings. Over his tenure, Mahon has executed 160 transactions exclusively in UTHR, with total sales exceeding $86.7 million against buys of $26.8 million, reflecting a net disposition trend. His recent activity has intensified this sell-side bias, with 19 sales since February 2026 and zero buys. Notably, on March 19, 2026, he offloaded shares across multiple transactions totaling over $4.2 million, including a single sale valued at $1.48 million. Earlier that month, on March 5, he executed a cluster of sales worth approximately $3.9 million, with individual transactions ranging from $97,530 to $769,310. The largest recent dispositions occurred on March 15, 2026, with two sales worth $2.09 million and $2.39 million, respectively, classified as derivative transactions (code F). While Mahon retains significant holdings—evidenced by periodic acquisitions via equity awards (code M)—his recent actions suggest a deliberate reduction in exposure to UTHR shares. The absence of buying activity during this period reinforces a one-way flow of disposals, though the sales appear structured rather than abrupt, possibly indicating planned liquidity events.
AI-assisted summary